APO RESEARCH · REPORT
Cyclophosphamide
Cyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma.
Product & engineering
Understand the product.
Cyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma.
Selected research
Industry Research
Cyclophosphamide Industry Research Report 2026
Market perspective
Cyclophosphamide (CP), also known as cytophosphane among other names, is a medication used as chemotherapy and to suppress the immune system. As chemotherapy it is used to treat lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, small cell lung cancer, neuroblastoma, and sarcoma.
Top 8 manufacturers took 75.4% market share in 2019.
Report Scope
Read the full market overview
This report quantifies the global Cyclophosphamide market in terms of revenue (US$ million) and, where applicable, sales volume (Person), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Person) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cyclophosphamide Market by Company
Baxter
Novartis
Hikma Pharmaceuticals
Amneal Pharmaceuticals LLC
Jiangsu Hengrui Medicine
NorthStar Rx LLC
GLS Pharma
CSC Pharmaceuticals International
Cyclophosphamide Segment by Type
High-Dose
Low-Dose
Cyclophosphamide Segment by Application
Cancer
Autoimmune Diseases
AL Amyloidosis
Others
Cyclophosphamide Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cyclophosphamide market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cyclophosphamide and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cyclophosphamide.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Cyclophosphamide manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Cyclophosphamide by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Cyclophosphamide in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- High-Dose
- Low-Dose
Applications
- Cancer
- Autoimmune Diseases
- AL Amyloidosis
- Others
Companies covered
- Baxter
- Novartis
- Hikma Pharmaceuticals
- Amneal Pharmaceuticals LLC
- Jiangsu Hengrui Medicine
- NorthStar Rx LLC
- GLS Pharma
- CSC Pharmaceuticals International
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Cyclophosphamide Market Size (2021-2032)
- 2.2.2 Global Cyclophosphamide Sales (2021-2032)
- 2.2.3 Global Cyclophosphamide Market Average Price (2021-2032)
- 2.3 Cyclophosphamide by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 High-Dose
- 2.3.3 Low-Dose
- 2.4 Cyclophosphamide by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cancer
- 2.4.3 Autoimmune Diseases
- 2.4.4 AL Amyloidosis
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Cyclophosphamide Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Cyclophosphamide Sales (Person) of Manufacturers (2021-2026)
- 3.3 Global Cyclophosphamide Revenue of Manufacturers (2021-2026)
- 3.4 Global Cyclophosphamide Average Price by Manufacturers (2021-2026)
- 3.5 Global Cyclophosphamide Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Cyclophosphamide, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Cyclophosphamide, Product Type & Application
- 3.8 Global Manufacturers of Cyclophosphamide, Established Date
- 3.9 Global Cyclophosphamide Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Baxter
- 4.1.1 Baxter Company Information
- 4.1.2 Baxter Business Overview
- 4.1.3 Baxter Cyclophosphamide Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Baxter Cyclophosphamide Product Portfolio
- 4.1.5 Baxter Recent Developments
- 4.2 Novartis
- 4.2.1 Novartis Company Information
- 4.2.2 Novartis Business Overview
- 4.2.3 Novartis Cyclophosphamide Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Novartis Cyclophosphamide Product Portfolio
- 4.2.5 Novartis Recent Developments
- 4.3 Hikma Pharmaceuticals
- 4.3.1 Hikma Pharmaceuticals Company Information
- 4.3.2 Hikma Pharmaceuticals Business Overview
- 4.3.3 Hikma Pharmaceuticals Cyclophosphamide Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Hikma Pharmaceuticals Cyclophosphamide Product Portfolio
- 4.3.5 Hikma Pharmaceuticals Recent Developments
- 4.4 Amneal Pharmaceuticals LLC
- 4.4.1 Amneal Pharmaceuticals LLC Company Information
- 4.4.2 Amneal Pharmaceuticals LLC Business Overview
- 4.4.3 Amneal Pharmaceuticals LLC Cyclophosphamide Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Amneal Pharmaceuticals LLC Cyclophosphamide Product Portfolio
- 4.4.5 Amneal Pharmaceuticals LLC Recent Developments
- 4.5 Jiangsu Hengrui Medicine
- 4.5.1 Jiangsu Hengrui Medicine Company Information
- 4.5.2 Jiangsu Hengrui Medicine Business Overview
- 4.5.3 Jiangsu Hengrui Medicine Cyclophosphamide Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Jiangsu Hengrui Medicine Cyclophosphamide Product Portfolio
- 4.5.5 Jiangsu Hengrui Medicine Recent Developments
- 4.6 NorthStar Rx LLC
- 4.6.1 NorthStar Rx LLC Company Information
- 4.6.2 NorthStar Rx LLC Business Overview
- 4.6.3 NorthStar Rx LLC Cyclophosphamide Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 NorthStar Rx LLC Cyclophosphamide Product Portfolio
- 4.6.5 NorthStar Rx LLC Recent Developments
- 4.7 GLS Pharma
- 4.7.1 GLS Pharma Company Information
- 4.7.2 GLS Pharma Business Overview
- 4.7.3 GLS Pharma Cyclophosphamide Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 GLS Pharma Cyclophosphamide Product Portfolio
- 4.7.5 GLS Pharma Recent Developments
- 4.8 CSC Pharmaceuticals International
- 4.8.1 CSC Pharmaceuticals International Company Information
- 4.8.2 CSC Pharmaceuticals International Business Overview
- 4.8.3 CSC Pharmaceuticals International Cyclophosphamide Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CSC Pharmaceuticals International Cyclophosphamide Product Portfolio
- 4.8.5 CSC Pharmaceuticals International Recent Developments
5 Global Cyclophosphamide Market Scenario by Region
- 5.1 Global Cyclophosphamide Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Cyclophosphamide Sales by Region: 2021-2032
- 5.2.1 Global Cyclophosphamide Sales by Region: 2021-2026
- 5.2.2 Global Cyclophosphamide Sales by Region: 2027-2032
- 5.3 Global Cyclophosphamide Revenue by Region: 2021-2032
- 5.3.1 Global Cyclophosphamide Revenue by Region: 2021-2026
- 5.3.2 Global Cyclophosphamide Revenue by Region: 2027-2032
- 5.4 North America Cyclophosphamide Market Facts & Figures by Country
- 5.4.1 North America Cyclophosphamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Cyclophosphamide Sales by Country (2021-2032)
- 5.4.3 North America Cyclophosphamide Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Cyclophosphamide Market Facts & Figures by Country
- 5.5.1 Europe Cyclophosphamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Cyclophosphamide Sales by Country (2021-2032)
- 5.5.3 Europe Cyclophosphamide Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Cyclophosphamide Market Facts & Figures by Country
- 5.6.1 Asia Pacific Cyclophosphamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Cyclophosphamide Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Cyclophosphamide Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Cyclophosphamide Market Facts & Figures by Country
- 5.7.1 South America Cyclophosphamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Cyclophosphamide Sales by Country (2021-2032)
- 5.7.3 South America Cyclophosphamide Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Cyclophosphamide Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Cyclophosphamide Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Cyclophosphamide Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Cyclophosphamide Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Cyclophosphamide Sales by Type (2021-2032)
- 6.1.1 Global Cyclophosphamide Sales by Type (2021-2032) & (Person)
- 6.1.2 Global Cyclophosphamide Sales Market Share by Type (2021-2032)
- 6.2 Global Cyclophosphamide Revenue by Type (2021-2032)
- 6.2.1 Global Cyclophosphamide Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Cyclophosphamide Revenue Market Share by Type (2021-2032)
- 6.3 Global Cyclophosphamide Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Cyclophosphamide Sales by Application (2021-2032)
- 7.1.1 Global Cyclophosphamide Sales by Application (2021-2032) & (Person)
- 7.1.2 Global Cyclophosphamide Sales Market Share by Application (2021-2032)
- 7.2 Global Cyclophosphamide Revenue by Application (2021-2032)
- 7.2.1 Global Cyclophosphamide Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Cyclophosphamide Revenue Market Share by Application (2021-2032)
- 7.3 Global Cyclophosphamide Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Cyclophosphamide Value Chain Analysis
- 8.1.1 Cyclophosphamide Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Cyclophosphamide Production Mode & Process
- 8.2 Cyclophosphamide Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Cyclophosphamide Distributors
- 8.2.3 Cyclophosphamide Customers
9 Global Cyclophosphamide Analyzing Market Dynamics
- 9.1 Cyclophosphamide Industry Trends
- 9.2 Cyclophosphamide Industry Drivers
- 9.3 Cyclophosphamide Industry Opportunities and Challenges
- 9.4 Cyclophosphamide Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst